Specific inhibitor of Notch‑3 enhances the sensitivity of NSCLC cells to gemcitabine-Reference-Cited by-同舟云学术

Specific inhibitor of Notch‑3 enhances the sensitivity of NSCLC cells to gemcitabine

Published:2018-05-16 Issue: Volume: Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Hu Bi‑Dan¹,Guo Jia¹,Ye Yuan‑Zi²,Du Ting¹,Cheng Chun‑Song³,Jiang Qian¹,Liu Ruo‑Nan¹,Zhang Yan‑Bei¹

Affiliation:

1. Department of Respiratory and Critical Care, Anhui Geriatric Institute, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R.ï¿½China

2. Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia

3. State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau 999078, SAR, P.R.ï¿½China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Notch signaling and targeted therapy in non-small cell lung cancer;Cancer Letters;2024-03

2. Nanomedicine Combats Drug Resistance in Lung Cancer;Advanced Materials;2023-11-27

3. Chemoresistance Mechanisms in Non-Small Cell Lung Cancer—Opportunities for Drug Repurposing;Applied Biochemistry and Biotechnology;2023-09-18

4. NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma;Journal of Cancer Research and Clinical Oncology;2023-02-07

5. Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives;Cancers;2021-10-12